The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression The hematopoietic malignancy, chronic myeloid leukemia (CML) is caused by BCR/ABL, the product of the t(9;22) chromosomal translocation (Deininger et al. 1 ). CML is characterized by abnormal progenitor cell growth and trafficking and premature release of these immature cells into the peripheral blood. Underlying mechanisms include defective adhesion of CML cells to stroma and fibronectin owing to aberrant expression/function of integrins, and in particular, the influence of BCR-ABL on molecules associated with cell adhesion (Wertheim et al. 2 ). In addition to playing a role in abnormal CML trafficking, stromal cells also contribute to minimal residual disease (MRD) in patients treated with tyrosine kinase inhibitors (TKIs), such as imatinib (Buchdunger et al. 3 ) and nilotinib (Weisberg et al. 4 ). In a recent report (Zhang et al. 5 ), a transgenic mouse model was employed to investigate the influence of the bone marrow (BM) microenvironment on leukemia stem cells with long-term hematopoietic stem cell phenotype in CML. Higher leukemia cell production of G-CSF and lower BM expression of CXCL12 were associated with a decrease in leukemia stem cell homing and withholding of cells in the BM. In addition, aberrant BM expression of cytokines potentiated CML stem cell proliferation yet impaired that of normal stem cells, all of which were partly reversed by imatinib treatment. Disease relapse occurs in more than half of imatinib-treated CML patients (Mahon et al. 6 ). Stromal-derived cytokines that diminish TKI-induced apoptosis have been implicated in MRD that, despite expressing BCR-ABL, is comprised of ABL inhibitor-unresponsive CD34 þ cells (Konig et al.
7
).
Whereas CXCR4 expression and signaling are decreased in cells that express BCR-ABL, TKI (i.e., imatinib or nilotinib) inhibition of BCR-ABL kinase activity upregulates CXCR4 surface expression, which causes CML cells to migrate to BM stroma where they are in a protective microenvironment (Jin et al.; 8 Dillmann et al. 9 ). The BM is hypoxic in nature, and hypoxia potentiates the survival of quiescent CML leukemia-initiating cells. Of relevance, imatinib resistance has been shown to develop in CML leukemia-initiating cells cultured under hypoxic conditions (Giuntoli et al. 10 ) . A regulator of the hypoxic response, hypoxia-inducible factor-1a (Hif1a), was recently shown in a CML mouse model to be required for CML leukemia stem cell survival (Zhang et al. 11 ). CXCR4 antagonists, such as plerixafor, steer leukemic cells away from the protective microenvironment, and hence are potentially effective in potentiating the apoptosis-inducing effects of TKIs like imatinib and nilotinib (Zeng et al.; 12 Weisberg et al. 13 ). These results highlight the important role of the SDF-1/CXCR4 axis in stromal-associated drug resistance in CML and point toward CXCR4 as a potential therapeutic target in the treatment of CML and prevention or eradication of MRD. In addition to CML, we have previously shown that plerixafor potentiated the effects of chemotherapy in multiple myeloma (Azab et al. 14 ) . We have recently demonstrated that hypoxia activates epithelial-mesenchymal transition-associated processes in multiple myeloma; specifically, hypoxia downregulated the expression of E-cadherin, which induced egress of cells from the BM, and in parallel it upregulated CXCR4 expression, which increased cell migration and homing to new BM niches (Azab et al. 13 ). In the present study, we were interested in determining the effect of Accepted article preview online 5 December 2012; advance online publication, 4 January 2013
Letters to the Editor hypoxia on the expression of adhesion molecules such as CXCR4 and E-cadherin in CML, and its role in leukemia progression in vivo.
We have tested the relationship between tumor progression and hypoxia in CML cells in the BM and in the PB in vivo. Injection of different amount of CML cells resulted in correlative increased involvement of CML cells in the BM; however, the percent of CML cells in the PB did not change with increasing the number of cells injected ( Figure 1a ). Testing the level of hypoxia in CML cells isolated from mice with different levels of tumor progression in the BM revealed that CML cells in the BM showed increased hypoxia staining in BM with tumor progression, whereas CML cells in the PB did not show similarly increased hypoxia staining ( Figure 1b) . These results are different from our previous findings in multiple myeloma (MM), in which we found a correlation between the numbers of circulating tumor cells and the levels of hypoxia in the BM, and we found that circulating MM cells showed high staining for hypoxia markers (Azab et al. 15 ). This might be the result of the differences in the pathophysiology of the diseases in which MM cells were found to be dependent on interaction with the BM for progression (Azab et al. 14 ) . Leukemia is a circulating disease by definition, and its dependence on the BM seems to be less than that of MM. Another possible explanation of these differences is that the circulating cells may originate from nonhypoxic infiltrated organs such as the liver and spleen. More studies are warranted to define the mechanism of circulation in CML.
We then measured the correlation between hypoxia in the BM and the expression of E-cadherin and CXCR4. The expression of E-cadherin was inversely correlated and the CXCR4 was directly correlated with hypoxia in the CML cells in the BM (Figures 1c and d , respectively ). The expression of E-cadherin and CXCR4 in CML cells in the PB did not correlate with hypoxia in the BM, in agreement with the finding that these cells did not show change in their hypoxic state in correlation with the tumor progression in the BM.
To test the effect of hypoxia on CML cell-trafficking, we tested the effect of hypoxia on adhesion and chemotaxis of CML cells in vitro using incubation under hypoxic conditions (1% O2). Hypoxia decreased the expression of E-cadherin in CML cells (Figure 2a) , and consequently decreased the adhesion of CML cells to BM stroma derived from CML patients (Figure 2b ). The effect of hypoxia on adhesion was more obvious than the effect on E-Cadherin, therefore it is possible that other adhesion molecules are involved in this process, and further investigation is needed to determine these. Similarly, hypoxia increased the expression of CXCR4 in CML cells (Figure 2c) , and consequently increased the chemotaxis of CML cells to SDF1 (Figure 2d ). These results are in agreement with our previous finding in MM, in which hypoxia decreased the expression of E-cadherin and adhesion, and increased the expression of CXCR4 and chemotaxis of MM cells, to promote metastasis. cells to groups of three mice each). Following 10 days, mice were treated with the hypoxia marker PIM (100 mg/kg IP injection). After 4 h, peripheral blood (PB) was drawn and BM was isolated from the femurs. Red blood cells in PB and BM samples were lysed; mononuclear cells were obtained by centrifugation, followed by washing with cold PBS. Mononuclear cells obtained from PB and BM of mice at different stages of CML were then fixed and permeablized with 90% cold ethanol in PBS, washed with cold PBS and blocked with 5% FBS in PBS. Cells were stained with primary mouse-anti-E-cadherin antibody and rabbit-anti-c-Abl, followed by a secondary Alexa-Fluor-594-goat-anti-mouse antibody (Ex ¼ 532 nm, Filter 610/20 nm) and Alexa-Fluor-488-goat-anti-rabbit antibody (Invitrogen, Carlsbad, CA, USA) (Ex ¼ 488 nm, Filter 510/20 nm). Cells were then washed twice with cold PBS and stained with APC-anti-PIM (Ex ¼ 635 nm, Filter 660/20 nm) and PE-mouse-anti-human-CXCR4 (Clone 12G5) (BD, Franklin Lakes, NJ, USA) (Ex ¼ 488 nm, Filter 575/26 nm) and samples were analyzed by flow cytometry using BD-FACS-Aria (Franklin Lakes, NJ, USA). For these studies, BCR-ABL tyrosine kinase-expressing murine 32D.p210 cells were developed. Pimonidazole (PIM) and anti-PIM mAb were obtained from Store (Burlington, MA, USA).
We conclude that hypoxia induces cell egress from the BM in CML. We hypothesize that this is a mechanism shared by hematopoietic malignancies that depend on the BM for their progression. Studies to confirm this mechanism in other hematologic malignancies, and the development of new therapeutic entities to target the hypoxic response to prevent progression of hematologic malignancies are warranted.
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Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells Acute myeloid leukemia (AML) is the most commonly diagnosed cancer affecting the myeloid lineage of hematopoiesis in adults. Although standard chemotherapy for AML treatment initially leads to complete remission (CR) in 60-80% of patients, 50-70% of patients relapse after CR in the first 3 years.
1 Therefore, the search for new treatment strategies to eliminate minimal residual disease has encouraged targeted immunotherapeutic approaches. A promising target is the 67 kDa transmembrane cell surface glycoprotein CD33, which is a common and widespread marker for acute leukemias arising from the myeloid lineage. 2 In addition, it is also assumed to be expressed on leukemic stem and progenitor cells. 3, 4 Targeting CD33 thus might be attractive for the treatment of AML patients where CR cannot be achieved after initial standard chemotherapy, but also for patients with minimal residual disease after first cytomorphologic remission of the disease. Therefore, a series of anti-CD33-based therapeutic concepts were followed over the past decades including the retargeting of T cells with bispecific antibodies (bsAbs). 5, 6 Conflicting data concerning cross-reactivity of anti-CD33 Abs with human stem cell progenitors (HSCPs) are reported in the literature, 5,7 raising the question whether or not hematopoiesis will be suppressed after a CD33-specific retargeting of cytotoxic effector T cells. Based on novel murine anti-CD33 and anti-CD3 monoclonal antibodies (mAbs), we recently established a novel bsAb for retargeting of T cells to AML blasts. 8, 9 In light of a future clinical application, we have now humanized this bsAb construct to reduce the risk of human anti-mouse antibody responses and optimized its cytotoxic potential against AML blasts. The resulting fully humanized bsAb CD33-CD3 is capable of efficiently redirecting T cells to AML blasts in picomolar concentrations and does not impair the multilineage reconstitution potential of HSCPs.
For humanization, the CDR regions of both Ab-binding domains of the previously described anti-CD3 and anti-CD33 mAbs were in silico engrafted to the best fitting human framework regions. 9, 10 Subsequently, the variable light and heavy chains were synthesized and arranged in tandem format by using glycineserine linkers as connecting elements. [8] [9] [10] To evaluate functional efficacy of the novel humanized bsAb CD33-CD3, both chromium release and flow cytometry-based assays were performed as described previously. [9] [10] [11] Freshly isolated human pan T cells served as effector cells in all in vitro and in vivo assays (Figure 1 ). By performing a flow cytometry-based assay using decreasing Ab concentrations, we could show that the bsAb efficiently redirects T cells to eradicate CD33 þ AML cells even at picomolar concentrations (Figure 1a, n ¼ 4) . In addition, killing properties of bsAbredirected T cells were examined by performing chromium release assays against various AML cell lines. As shown in Figure 1b Accepted article preview online 17 January 2013; advance online publication, 8 February 2013 
